NfL as a Predictor of GdE Lesions in Patients With Relapsing Multiple Sclerosis Treated With Ozanimod in the Phase 2 RADIANCE Trial (P1-3.012)

NfL as a Predictor of GdE Lesions in Patients With Relapsing Multiple Sclerosis Treated With Ozanimod in the Phase 2 RADIANCE Trial (P1-3.012)

Abstract only

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neurology 2023-04, Vol.100 (17_supplement_2)
Hauptverfasser: Harris, Sarah, Vermersch, Patrick, Montalban, Xavier, Hartung, Hans-Peter, Kappos, Ludwig, Southworth, Harry, Sheffield, James K., Silva, Diego, Cohen, Jeffrey A.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 17_supplement_2
container_start_page
container_title Neurology
container_volume 100
creator Harris, Sarah
Vermersch, Patrick
Montalban, Xavier
Hartung, Hans-Peter
Kappos, Ludwig
Southworth, Harry
Sheffield, James K.
Silva, Diego
Cohen, Jeffrey A.
description Abstract only
doi_str_mv 10.1212/WNL.0000000000202232
format Article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1212_WNL_0000000000202232</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1212_WNL_0000000000202232</sourcerecordid><originalsourceid>FETCH-crossref_primary_10_1212_WNL_00000000002022323</originalsourceid><addsrcrecordid>eNqdj09Lw0AQxRdRMFa_gYc56iFxd6NtPJYa_0CMoRbqLSzJxIxsk7CzHvRD-JlNUXrw6LsMvPfmwU-IUyUjpZW-WOdZJHfSUutY74lAXelpOI31y74IRjsJ42SWHIoj5jcpx3B2HYivvMnAMBgoHNZU-d5B38BdnUKGTH3HQB0UxhN2nmFNvoUlWjMwda_w-G49DRbhubLoeiaGlUPjsf5pPn2ajjZ9vd3wLULRGkbQsJzfPMzzRTq2yVg4K1QYR1Lp82Nx0BjLePJ7J-LyNl0t7sNqXGeHTTk42hj3USpZbtnLkb38yx7_8-0boZRfzQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>NfL as a Predictor of GdE Lesions in Patients With Relapsing Multiple Sclerosis Treated With Ozanimod in the Phase 2 RADIANCE Trial (P1-3.012)</title><source>Journals@Ovid Ovid Autoload</source><source>Alma/SFX Local Collection</source><creator>Harris, Sarah ; Vermersch, Patrick ; Montalban, Xavier ; Hartung, Hans-Peter ; Kappos, Ludwig ; Southworth, Harry ; Sheffield, James K. ; Silva, Diego ; Cohen, Jeffrey A.</creator><creatorcontrib>Harris, Sarah ; Vermersch, Patrick ; Montalban, Xavier ; Hartung, Hans-Peter ; Kappos, Ludwig ; Southworth, Harry ; Sheffield, James K. ; Silva, Diego ; Cohen, Jeffrey A.</creatorcontrib><description>Abstract only</description><identifier>ISSN: 0028-3878</identifier><identifier>EISSN: 1526-632X</identifier><identifier>DOI: 10.1212/WNL.0000000000202232</identifier><language>eng</language><ispartof>Neurology, 2023-04, Vol.100 (17_supplement_2)</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Harris, Sarah</creatorcontrib><creatorcontrib>Vermersch, Patrick</creatorcontrib><creatorcontrib>Montalban, Xavier</creatorcontrib><creatorcontrib>Hartung, Hans-Peter</creatorcontrib><creatorcontrib>Kappos, Ludwig</creatorcontrib><creatorcontrib>Southworth, Harry</creatorcontrib><creatorcontrib>Sheffield, James K.</creatorcontrib><creatorcontrib>Silva, Diego</creatorcontrib><creatorcontrib>Cohen, Jeffrey A.</creatorcontrib><title>NfL as a Predictor of GdE Lesions in Patients With Relapsing Multiple Sclerosis Treated With Ozanimod in the Phase 2 RADIANCE Trial (P1-3.012)</title><title>Neurology</title><description>Abstract only</description><issn>0028-3878</issn><issn>1526-632X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqdj09Lw0AQxRdRMFa_gYc56iFxd6NtPJYa_0CMoRbqLSzJxIxsk7CzHvRD-JlNUXrw6LsMvPfmwU-IUyUjpZW-WOdZJHfSUutY74lAXelpOI31y74IRjsJ42SWHIoj5jcpx3B2HYivvMnAMBgoHNZU-d5B38BdnUKGTH3HQB0UxhN2nmFNvoUlWjMwda_w-G49DRbhubLoeiaGlUPjsf5pPn2ajjZ9vd3wLULRGkbQsJzfPMzzRTq2yVg4K1QYR1Lp82Nx0BjLePJ7J-LyNl0t7sNqXGeHTTk42hj3USpZbtnLkb38yx7_8-0boZRfzQ</recordid><startdate>20230425</startdate><enddate>20230425</enddate><creator>Harris, Sarah</creator><creator>Vermersch, Patrick</creator><creator>Montalban, Xavier</creator><creator>Hartung, Hans-Peter</creator><creator>Kappos, Ludwig</creator><creator>Southworth, Harry</creator><creator>Sheffield, James K.</creator><creator>Silva, Diego</creator><creator>Cohen, Jeffrey A.</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20230425</creationdate><title>NfL as a Predictor of GdE Lesions in Patients With Relapsing Multiple Sclerosis Treated With Ozanimod in the Phase 2 RADIANCE Trial (P1-3.012)</title><author>Harris, Sarah ; Vermersch, Patrick ; Montalban, Xavier ; Hartung, Hans-Peter ; Kappos, Ludwig ; Southworth, Harry ; Sheffield, James K. ; Silva, Diego ; Cohen, Jeffrey A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-crossref_primary_10_1212_WNL_00000000002022323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Harris, Sarah</creatorcontrib><creatorcontrib>Vermersch, Patrick</creatorcontrib><creatorcontrib>Montalban, Xavier</creatorcontrib><creatorcontrib>Hartung, Hans-Peter</creatorcontrib><creatorcontrib>Kappos, Ludwig</creatorcontrib><creatorcontrib>Southworth, Harry</creatorcontrib><creatorcontrib>Sheffield, James K.</creatorcontrib><creatorcontrib>Silva, Diego</creatorcontrib><creatorcontrib>Cohen, Jeffrey A.</creatorcontrib><collection>CrossRef</collection><jtitle>Neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Harris, Sarah</au><au>Vermersch, Patrick</au><au>Montalban, Xavier</au><au>Hartung, Hans-Peter</au><au>Kappos, Ludwig</au><au>Southworth, Harry</au><au>Sheffield, James K.</au><au>Silva, Diego</au><au>Cohen, Jeffrey A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>NfL as a Predictor of GdE Lesions in Patients With Relapsing Multiple Sclerosis Treated With Ozanimod in the Phase 2 RADIANCE Trial (P1-3.012)</atitle><jtitle>Neurology</jtitle><date>2023-04-25</date><risdate>2023</risdate><volume>100</volume><issue>17_supplement_2</issue><issn>0028-3878</issn><eissn>1526-632X</eissn><abstract>Abstract only</abstract><doi>10.1212/WNL.0000000000202232</doi></addata></record>
fulltext fulltext
identifier ISSN: 0028-3878
ispartof Neurology, 2023-04, Vol.100 (17_supplement_2)
issn 0028-3878
1526-632X
language eng
recordid cdi_crossref_primary_10_1212_WNL_0000000000202232
source Journals@Ovid Ovid Autoload; Alma/SFX Local Collection
title NfL as a Predictor of GdE Lesions in Patients With Relapsing Multiple Sclerosis Treated With Ozanimod in the Phase 2 RADIANCE Trial (P1-3.012)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T17%3A43%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=NfL%20as%20a%20Predictor%20of%20GdE%20Lesions%20in%20Patients%20With%20Relapsing%20Multiple%20Sclerosis%20Treated%20With%20Ozanimod%20in%20the%20Phase%202%20RADIANCE%20Trial%20(P1-3.012)&rft.jtitle=Neurology&rft.au=Harris,%20Sarah&rft.date=2023-04-25&rft.volume=100&rft.issue=17_supplement_2&rft.issn=0028-3878&rft.eissn=1526-632X&rft_id=info:doi/10.1212/WNL.0000000000202232&rft_dat=%3Ccrossref%3E10_1212_WNL_0000000000202232%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true